Literature DB >> 21430597

T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery.

R Mark Richardson1, Francisco Gimenez, Ernesto Aguilar Salegio, Xiaomin Su, John Bringas, Mitchel S Berger, Krystof S Bankiewicz.   

Abstract

BACKGROUND: Real-time convection-enhanced delivery (RCD) of adeno-associated viral vectors by co-infusion of gadoteridol allows T1 magnetic resonance imaging (T1 MRI) prediction of areas of subsequent gene expression. The use of T2 MRI in RCD is less developed. In addition, the effect of flushing a dead-space volume on subsequent distribution of a therapeutic agent is not known.
OBJECTIVE: The value of T2 MRI in RCD was investigated by comparing distribution volumes of saline with immediately after T1 RCD of gadoteridol and by comparing T2, T1, and transgene distribution patterns after viral vector RCD.
METHODS: Adult nonhuman primates underwent saline infusion/T2 acquisition, immediately followed by gadoteridol infusion/T1 acquisition in the putamen and brainstem. Distribution volumes and spatial patterns were analyzed. Gadoteridol and adeno-associated virus encoding human aromatic l-amino acid decarboxylase (AAV2-hAADC) were co-infused under alternating T2/T1 acquisition in the thalamus, and hyperintense areas were compared with areas of subsequent transgene expression.
RESULTS: Ratios of distribution volume to infusion volume were similar between saline and gadoteridol RCD. Spatial overlap correlated well between T2 and T1 images. The second infusate followed a spatiotemporal pattern similar to that of the first, filling the target area before developing extra-target distribution. Areas of human L-amino acid decarboxylase expression correlated well with areas of both T1 and T2 hyperintensity observed during RCD.
CONCLUSION: Accuracy of cannula placement and initial infusate distribution may be safely determined by saline infusion without significantly altering the subsequent distribution of the tracer agent. T2 RCD provides detection of intraparenchymal convection- enhanced delivery in the uninjured brain and may predict subsequent distribution of a transgene after viral vector infusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430597     DOI: 10.1227/NEU.0b013e318217217e

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  14 in total

Review 1.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

2.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.

Authors:  Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-04-10       Impact factor: 5.695

Review 3.  Imaging of Convective Drug Delivery in the Nervous System.

Authors:  Russell R Lonser
Journal:  Neurosurg Clin N Am       Date:  2017-08-19       Impact factor: 2.509

Review 4.  Guided delivery of adeno-associated viral vectors into the primate brain.

Authors:  Ernesto A Salegio; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof Bankiewicz
Journal:  Adv Drug Deliv Rev       Date:  2011-10-20       Impact factor: 15.470

5.  Evaluation of pressure-driven brain infusions in nonhuman primates by intra-operative 7 Tesla MRI.

Authors:  Kathryn H Rosenbluth; Alastair J Martin; John Bringas; Krystof S Bankiewicz
Journal:  J Magn Reson Imaging       Date:  2012-08-07       Impact factor: 4.813

Review 6.  Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies.

Authors:  Arman Jahangiri; Aaron T Chin; Patrick M Flanigan; Rebecca Chen; Krystof Bankiewicz; Manish K Aghi
Journal:  J Neurosurg       Date:  2016-04-01       Impact factor: 5.115

7.  SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.

Authors:  Waldy San Sebastian; Adrian P Kells; John Bringas; Lluis Samaranch; Piotr Hadaczek; Agnieszka Ciesielska; Michael Macayan; Phillip J Pivirotto; John Forsayeth; Sheryl Osborne; J Fraser Wright; Foad Green; Gregory Heller; Krystof S Bankiewicz
Journal:  Mol Ther Methods Clin Dev       Date:  2014-10-15       Impact factor: 6.698

8.  Automated segmentation tool for brain infusions.

Authors:  Kathryn Hammond Rosenbluth; Francisco Gimenez; Adrian P Kells; Ernesto A Salegio; Gabriele M Mittermeyer; Kevin Modera; Anmol Kohal; Krystof S Bankiewicz
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

9.  Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.

Authors:  Massimo S Fiandaca; Krystof S Bankiewicz; Howard J Federoff
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-04

Review 10.  Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery.

Authors:  Gurwattan S Miranpuri; Lauren Kumbier; Angelica Hinchman; Dominic Schomberg; Anyi Wang; Hope Marshall; Ken Kubota; Chris Ross; Karl Sillay
Journal:  Ann Neurosci       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.